Phase I study of maytansine using a 3-day schedule

Area of Science:

• Oncology
• Pharmacology
• Antibiotics

Background:

• Maytansine is a novel ansa macrolide antibiotic with potential antitumor properties.
• Phase I clinical trials are essential for evaluating the safety and efficacy of new cancer therapeutics.

Purpose of the Study:

• To assess the safety and tolerability of maytansine in cancer patients.
• To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of maytansine.
• To explore preliminary evidence of antitumor activity for maytansine.

Main Methods:

• A phase I clinical trial involving 60 patients with various advanced cancers.
• Administration of maytansine at doses ranging from 0.01 to 0.9 mg/m2 over 3 days.
• Monitoring of toxic effects, including gastrointestinal, dermatological, and hematological parameters, as well as liver function tests.

Main Results:

• The primary toxic effects observed were nausea, vomiting, diarrhea, stomatitis, and alopecia.
• Superficial phlebitis occurred when maytansine was diluted in less than 250 ml.
• Myelosuppression was infrequent and often associated with abnormal liver function tests.
• Antitumor activity was noted in individual patients with melanoma, breast carcinoma, and head and neck clear cell carcinoma.

Conclusions:

• Maytansine exhibits antitumor activity in certain cancers with a manageable toxicity profile.
• The observed toxicities, such as phlebitis, can be mitigated by appropriate drug dilution.
• Further clinical investigations are justified to explore the therapeutic potential of maytansine in oncology.